Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.38 |
| ▸ | CA1 | P00915 | 8/20 | 0.37 |
| ▸ | CA2 | P00918 | 8/20 | 0.37 |
| ▸ | CA4 | P22748 | 8/20 | 0.37 |
| ▸ | CA9 | Q16790 | 8/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492365 | 0.91 | CHRM2 (0.39) | CYP3A4TSHRCYP2D6CA1CA2 | |
| SCHEMBL4978691 | 0.90 | ABHD6 (0.42) | CYP3A4TSHRCYP2D6ALDH1A1 | |
| SCHEMBL4290397 | 0.90 | CA1 (0.40) | CA1CA2CA4CA9 | |
| SCHEMBL3493603 | 0.89 | CA1 (0.43) | CYP3A4CA1CA2CA4CA9 | |
| SCHEMBL3495527 | 0.87 | CA1 (0.40) | CYP3A4TSHRCYP2D6CA1CA2 | |
| SCHEMBL3494132 | 0.87 | CA1 (0.41) | CYP3A4TSHRCYP2D6CA1CA2 | |
| SCHEMBL3493481 | 0.85 | CA1 (0.37) | CA1CA2CA4CA9 | |
| SCHEMBL3493970 | 0.85 | CA1 (0.39) | CA1CA2CA4CA9 | |
| SCHEMBL3493322 | 0.85 | USP19 (0.41) | CA1CA2CA4CA9 | |
| SCHEMBL4978695 | 0.84 | CYP2D6 (0.35) | CYP3A4TSHRCYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | CYP3A4 1555/4885TSHR 684/4885CYP2D6 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.